Rappta Therapeutics is a startup based in Finland, most recent round Series A, 2 tracked investors.
Based in Finland, Rappta Therapeutics is a startup. Its most recent tracked round is Series A. Brouky records 2 investors associated with the company.
Rappta Therapeutics is a late preclinical stage biopharmaceutical company focused on developing anti-cancer molecular glues that reactivate the tumor suppressor protein phosphatase 2A (PP2A). The company utilizes proprietary technology to target PP2A, a critical enzyme involved in regulating protein de-phosphorylation and tumor growth.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.